David Jones
Acute Care · Philadelphia, PANPI 1487799086
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Medtronic at 56.2% of the total. Reporting peaked in 2022 at $5,614 and has fallen 71.1% since, to $1,620 in 2025. Among acute care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $190.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Edwards Lifesciences$5K
- Teva Pharmaceuticals USA, Inc.$51
- Abbott$26
What the payments were for
- Consulting fees$9909%
- Speaking & faculty fees$3,59531%
- Travel & lodging$4,53140%
- Food & beverage$2,31620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 19 | $6,421 |
| Edwards Lifesciences | 38 | $4,934 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Abbott | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$4,401
- CoreValve Evolut$720
How this compares
$11,431 in reported general payments places this provider in the 95th percentile of 872 acute care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 49 | $300 |
Paid to pharmacies, not to this prescriber.
Other acute care in Philadelphia
- Kathryn GreenPhiladelphia$92K
- Caroline PratzPhiladelphia$77K
- Rebecca MarcantuonoPhiladelphia$17K
- Stephanie TothPhiladelphia$17K
- Colleen KollerPhiladelphia$11K
- Maura LevandowskiPhiladelphia$9K
- Christopher SipalaPhiladelphia$9K
- Amaryah YaegerPhiladelphia$7K
- Shane RudolphPhiladelphia$6K
- Elizabeth ThorntonPhiladelphia$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.